Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib
Nefrologia (Engl Ed). 2019 Jan-Feb;39(1):86-88.
doi: 10.1016/j.nefro.2018.02.005.
Epub 2018 Apr 30.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España. Electronic address: candelamoliz@gmail.com.
- 2 Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, España.
No abstract available
Publication types
-
Case Reports
-
Letter
-
Review
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Atypical Hemolytic Uremic Syndrome / chemically induced
-
Atypical Hemolytic Uremic Syndrome / drug therapy*
-
Complement Inactivating Agents / therapeutic use*
-
Female
-
Humans
-
Multiple Myeloma / drug therapy
-
Oligopeptides / adverse effects*
Substances
-
Antibodies, Monoclonal, Humanized
-
Complement Inactivating Agents
-
Oligopeptides
-
carfilzomib
-
eculizumab